Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the development of therapies for serious eye diseases, with a core emphasis on drug delivery to the back of the eye. The company operates within the ophthalmology and biotechnology industries, targeting retinal and choroidal diseases that can lead to vision loss. Its primary value proposition centers on its proprietary suprachoroidal drug delivery platform, which is designed to deliver therapeutics directly to the retina and choroid while potentially reducing off-target exposure.
Clearside was founded in 2011 and became publicly traded in 2016. The company’s strategy historically combined internal drug development with partnerships that leverage its delivery technology. Over time, Clearside shifted from a broad internal pipeline toward a more focused model emphasizing out-licensing and collaboration, particularly after encountering mixed clinical results and capital constraints. In 2023, the company filed for Chapter 11 bankruptcy protection, and its common stock began trading under the ticker CLSDQ, reflecting financial restructuring rather than ongoing commercial operations.
Business Operations
Clearside’s operations have primarily consisted of research and development activities related to ophthalmic therapeutics, rather than commercial manufacturing or sales. The company’s core business has been the development and clinical validation of its suprachoroidal injection technology, enabled by the SCS Microinjector®, and the advancement of drug candidates that use this delivery route. Revenue generation historically came from collaboration agreements, licensing arrangements, and upfront or milestone payments rather than product sales.
The company has operated mainly in the United States, with clinical trials conducted both domestically and internationally through contract research organizations. Clearside has relied on third-party manufacturers and research partners for clinical supply, regulatory support, and trial execution. Following its bankruptcy filing, ongoing operations have been significantly reduced, and public disclosures indicate that assets and intellectual property have been evaluated as part of restructuring and wind-down processes. Data inconclusive based on available public sources regarding the extent of current operational activity post-bankruptcy.
Strategic Position & Investments
Clearside’s strategic direction prior to bankruptcy focused on monetizing its delivery platform through partnerships with larger ophthalmology-focused pharmaceutical companies. Key initiatives included licensing agreements for the use of suprachoroidal delivery with both small-molecule and biologic therapies, allowing partners to apply the technology to their own drug candidates. The company also invested internally in clinical-stage assets, including CLS-AX (axitinib) for wet age-related macular degeneration and CLS-TA (triamcinolone acetonide) for retinal diseases.
The most notable strategic relationship was with Bausch + Lomb, which licensed the suprachoroidal platform for certain indications and contributed to Clearside’s validation within the ophthalmology market. However, limited access to capital and clinical setbacks constrained Clearside’s ability to advance its pipeline independently. Following the Chapter 11 filing, the strategic focus shifted toward asset preservation and potential sale or licensing of intellectual property. Data inconclusive based on available public sources regarding post-filing investment activity.
Geographic Footprint
Clearside Biomedical has been headquartered in the United States, with its principal executive offices historically located in Georgia. The company’s operational footprint has been primarily U.S.-based, reflecting its focus on early-stage research, regulatory engagement with the U.S. Food and Drug Administration, and collaboration with domestic partners.
Internationally, Clearside’s presence has been indirect, mainly through global clinical trial sites and multinational partners that operate across North America, Europe, and Asia-Pacific. The company has not maintained significant standalone international offices or commercial infrastructure. Its global influence has therefore been tied to the reach of its partners rather than direct foreign operations.
Leadership & Governance
Clearside has been led by executives with backgrounds in ophthalmology, pharmaceuticals, and medical device development, emphasizing scientific rigor and platform-driven innovation. Governance has followed standard U.S. public company practices, with oversight by a board of directors and adherence to SEC reporting requirements, including disclosures in SEC filings up to its bankruptcy proceedings.
Key executives prior to and during the restructuring period included:
- George Lasezkay – President and Chief Executive Officer
- Mark J. Shearman – Chief Medical Officer
- D. Craig Owens – Chief Financial Officer
- Charles A. Stout – Chief Business Officer
Leadership communications emphasized capital discipline, partnership-driven growth, and the long-term potential of suprachoroidal delivery, although financial constraints ultimately limited execution.